Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Taltz for Adult Psoriatic Arthritis

FirstWord Pharma news release; 2017 Dec 1

Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA). Taltz was first approved by the FDA in March 2016 for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Indications: Taltz is a humanized interleukin-17A antagonist indicated for the treatment of adults with active PsA.

Dosage/administration: For PsA, the recommended dose is 160 mg by subcutaneous injection (2 80 mg injections) at week 0, followed by 80 mg every 4 weeks. For PsA patients with coexistent moderate-to-severe plaque psoriasis, refer to the dosing regimen for plaque psoriasis. Taltz may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (DMARD).

Adverse reactions: Most common (≥1%) adverse reactions associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.

Citation:

Lilly’s Taltz (ixekizumab) receives US FDA approval for the treatment of active psoriatic arthritis. [news release]. Indianapolis, IN: Eli Lilly and Company. December 2, 2017. www.firstwordpharma.com/node/1526704. Accessed December 4, 2017.

This Week's Must Reads

Hyperlipidemia Screening Poor in Persons with RA, Rheumatology (Oxford); ePub 2018 Jun 27; Schmidt, et al

Patient Confusion About Global Assessment for RA, Arthritis Care Res; ePub 2018 Jun 28; Hirsh, et al

Shared Decision-Making in RA at Point-of-Care, Arthritis Care Res; ePub 2018 Jun 28; Hsiao, et al

Examining Adiponectin Role in Rheumatoid Arthritis, PLoS One; ePub 2018 Jun 25; Hughes-Austin, et al

Online Resources for Disease Self-Management in RA, Clin Rheumatol; 2018 Jul; des Bordes, Gonzalez, et al

Must Reads in FDA Actions

FDA Approves Olumiant for Rheumatoid Arthritis, Eli Lilly, Incyte news release; 2018 Jun 1

FDA Approves Consensi for Osteoarthritis Pain, FirstWord Pharma news release; 2018 May 31

FDA Approves Prolia for GIOP in Men and Women, FirstWord Pharma news release; 2018 May 21

FDA Approves Xeljanz/Xeljanz XR for Adult PsA, Pfizer news release; 2017 Dec 14

FDA Approves New Pfizer Biosimilar Ixifi, Pfizer news release; 2017 Dec 13